Lyss A P, Loeb V
Cancer. 1984 Feb 1;53(3 Suppl):778-82. doi: 10.1002/1097-0142(19840201)53:3+<778::aid-cncr2820531328>3.0.co;2-7.
Most patients with locally advanced primary breast cancer and almost all patients with disseminated malignancy will ultimately die of their disease. Nevertheless, because breast cancer is one of the most responsive of the solid tumors to cytotoxic drugs, appropriately chosen chemotherapy can relieve symptoms and prolong survival. Adriamycin (doxorubicin) is the most effective among many useful single agents. Combination chemotherapy can augment responses with acceptable toxicity and, along with hormonal manipulation in selected situations, constitutes the standard of care for metastatic disease in 1983. In the interpretation of the clinical oncology literature, meticulous attention to prognostic factors and details of study design is necessary in order to assess the superiority of any particular regimen. Controlled clinical trials of various drug combinations and schedules are especially valuable. The use of an integrated clinical approach involving rational surgical, radiologic, and medical strategies in the management of locally advanced as well as metastatic breast cancer can provide not only meaningful palliation but prolonged disease-free survival for many patients with this common neoplasm.
大多数局部晚期原发性乳腺癌患者以及几乎所有播散性恶性肿瘤患者最终都会死于其疾病。然而，由于乳腺癌是实体瘤中对细胞毒性药物最敏感的肿瘤之一，适当选择的化疗可以缓解症状并延长生存期。阿霉素（多柔比星）是许多有效单药中最有效的。联合化疗可以在可接受的毒性下增强疗效，并且在某些情况下与激素治疗一起，构成了1983年转移性疾病的标准治疗方法。在解释临床肿瘤学文献时，为了评估任何特定方案的优越性，必须仔细关注预后因素和研究设计细节。各种药物组合和方案的对照临床试验尤其有价值。采用综合临床方法，包括在局部晚期以及转移性乳腺癌的管理中采用合理的手术、放射和医学策略，不仅可以为许多患有这种常见肿瘤的患者提供有意义的姑息治疗，还可以延长无病生存期。
